Your browser is no longer supported. Please, upgrade your browser.
MYGN [NASD]
Myriad Genetics, Inc.
Index- P/E- EPS (ttm)-3.27 Insider Own2.70% Shs Outstand75.00M Perf Week-7.18%
Market Cap2.18B Forward P/E82.30 EPS next Y0.34 Insider Trans-6.08% Shs Float73.40M Perf Month-8.80%
Income-244.40M PEG- EPS next Q-0.14 Inst Own- Short Float7.06% Perf Quarter11.28%
Sales557.00M P/S3.92 EPS this Y63.40% Inst Trans1.71% Short Ratio6.78 Perf Half Y107.93%
Book/sh11.75 P/B2.41 EPS next Y278.90% ROA-8.70% Target Price26.00 Perf Year86.99%
Cash/sh1.95 P/C14.50 EPS next 5Y8.10% ROE-13.50% 52W Range10.54 - 33.97 Perf YTD43.16%
Dividend- P/FCF- EPS past 5Y-21.20% ROI-6.10% 52W High-15.84% Beta1.61
Dividend %- Quick Ratio2.50 Sales past 5Y-16.50% Gross Margin68.00% 52W Low171.25% ATR1.68
Employees2700 Current Ratio2.70 Sales Q/Q53.70% Oper. Margin-35.10% RSI (14)46.78 Volatility4.89% 5.76%
OptionableYes Debt/Eq0.26 EPS Q/Q-782.00% Profit Margin-22.20% Rel Volume0.46 Prev Close28.31
ShortableYes LT Debt/Eq0.26 EarningsFeb 23 AMC Payout- Avg Volume763.52K Price28.59
Recom3.10 SMA20-3.66% SMA50-3.54% SMA20048.86% Volume39,315 Change0.99%
Sep-26-19Downgrade BofA/Merrill Neutral → Underperform $30 → $28
Aug-14-19Downgrade Piper Jaffray Overweight → Neutral $45 → $40
Aug-02-19Upgrade BofA/Merrill Underperform → Neutral
Aug-01-19Upgrade Barclays Underweight → Equal Weight $18 → $40
Jul-29-19Downgrade Needham Strong Buy → Hold
Jul-09-19Downgrade Cowen Outperform → Market Perform
Mar-12-19Reiterated Needham Strong Buy $37 → $41
Jan-03-19Initiated Needham Strong Buy $36
Nov-30-18Upgrade Goldman Sell → Neutral
Oct-10-18Upgrade Piper Jaffray Neutral → Overweight
Jul-11-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-29-18Initiated Goldman Sell $32
Jan-22-18Reiterated Barclays Equal Weight $30 → $35
Jan-05-18Initiated BTIG Research Buy $41
Oct-02-17Resumed Leerink Partners Mkt Perform $31
Aug-09-17Reiterated Barclays Equal Weight $28 → $26
Feb-08-17Upgrade Ladenburg Thalmann Sell → Neutral
Jan-18-17Initiated Deutsche Bank Sell $15
Oct-10-16Downgrade Ladenburg Thalmann Neutral → Sell
Apr-09-21 09:00AM  
Mar-31-21 08:00AM  
Mar-29-21 09:50AM  
07:05AM  
Mar-25-21 11:30AM  
Mar-24-21 06:05PM  
Mar-23-21 09:00PM  
Mar-05-21 10:03AM  
Mar-02-21 07:05AM  
Feb-23-21 08:30PM  
05:10PM  
04:05PM  
02:30PM  
Feb-22-21 10:14AM  
Feb-18-21 04:12PM  
Feb-16-21 04:05PM  
Feb-12-21 07:05AM  
Feb-11-21 04:05PM  
Feb-10-21 11:11AM  
Feb-08-21 07:05AM  
Feb-02-21 07:05AM  
Jan-28-21 12:32PM  
Jan-19-21 07:05AM  
Jan-18-21 08:45AM  
Jan-12-21 08:40AM  
Jan-11-21 02:05PM  
Jan-08-21 07:05AM  
Jan-06-21 10:20AM  
Jan-05-21 04:05PM  
Jan-04-21 07:05AM  
Dec-11-20 07:05AM  
Dec-09-20 11:30AM  
Nov-30-20 11:00AM  
Nov-17-20 07:05AM  
Nov-16-20 07:05AM  
Nov-15-20 08:00PM  
Nov-11-20 07:05AM  
Nov-10-20 08:25AM  
Nov-09-20 09:30PM  
03:15PM  
09:45AM  
08:00AM  
Nov-04-20 07:05AM  
Oct-26-20 12:31PM  
Oct-16-20 09:05AM  
Oct-15-20 07:05AM  
Oct-05-20 12:11PM  
Sep-16-20 10:58AM  
Sep-12-20 11:30AM  
Sep-10-20 07:05AM  
Sep-03-20 06:21PM  
Aug-24-20 11:04AM  
Aug-21-20 07:05AM  
Aug-14-20 04:05PM  
10:46AM  
06:36AM  
12:30AM  
Aug-13-20 06:15PM  
04:19PM  
04:08PM  
04:07PM  
Aug-12-20 11:01AM  
Aug-10-20 07:05AM  
Aug-06-20 07:05AM  
Aug-04-20 12:30PM  
Jul-31-20 07:05AM  
Jul-29-20 07:05AM  
Jul-28-20 07:05AM  
Jul-22-20 07:05AM  
Jul-07-20 06:32PM  
07:05AM  
Jul-06-20 10:04AM  
07:05AM  
Jul-05-20 08:56PM  
Jul-02-20 08:46AM  
Jul-01-20 07:05AM  
Jun-29-20 11:27AM  
Jun-25-20 07:05AM  
Jun-23-20 11:19AM  
Jun-22-20 10:32AM  
Jun-17-20 11:53AM  
Jun-15-20 07:05AM  
Jun-12-20 07:48PM  
Jun-11-20 02:22PM  
11:24AM  
Jun-09-20 10:23AM  
Jun-08-20 07:05AM  
Jun-05-20 09:00AM  
Jun-04-20 11:31AM  
07:05AM  
May-29-20 07:05AM  
May-28-20 07:05AM  
May-27-20 11:14AM  
May-26-20 09:27AM  
07:00AM  
May-20-20 08:12AM  
07:05AM  
May-18-20 11:55AM  
May-13-20 05:26PM  
May-11-20 07:05AM  
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hart Jayne B.Chief People OfficerMar 29Option Exercise22.2758,0001,291,860108,128Mar 30 06:31 PM
Hart Jayne B.Chief People OfficerMar 29Sale30.0058,0001,740,00080,128Mar 30 06:31 PM
LANCHBURY JERRY SChief Scientific OfficerFeb 16Option Exercise18.0080,0001,440,000321,020Feb 17 06:10 PM
LANCHBURY JERRY SChief Scientific OfficerFeb 16Sale29.7180,0002,377,048246,575Feb 17 06:10 PM
Parkinson PaulEVP Strategy and InnovationJan 08Sale25.0011,824295,60076,746Jan 11 04:40 PM
Phanstiel S. LouiseDirectorNov 11Buy16.6215,000249,33666,790Nov 12 08:57 AM
Ford AlexanderChief Operating OfficerSep 15Sale13.782,80438,630151,159Sep 16 09:56 AM